As briefly mentioned, it is important to emphasize that immunotherapies (including checkpoint inhibitors and vaccines) as well as angiogenesis therapies (VEGF therapies) are also at the forefront of NSCLC treatment. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.